Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus HEPARIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus HEPARIN SODIUM.
ANGIOMAX vs HEPARIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Heparin sodium potentiates the activity of antithrombin III, thereby inactivating thrombin and factor Xa, leading to inhibition of coagulation.
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
Intravenous: Initial bolus of 80 units/kg, then continuous infusion at 18 units/kg/h. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
The terminal elimination half-life of heparin is dose-dependent: approximately 30 minutes (low dose, e.g., 25 U/kg), 60 minutes (medium dose, 100 U/kg), and 150 minutes (high dose, 400 U/kg). Half-life increases with dose due to saturation of clearance mechanisms.
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Heparin is cleared primarily via the reticuloendothelial system and liver, with minimal renal excretion. Unchanged heparin is not significantly excreted in urine. Biliary/fecal elimination is negligible.
Category C
Category A/B
Anticoagulant
Anticoagulant